Anesthesia and Surgical Intensive Care Department, Faculty of Medicine, Aswan University, Aswan, Egypt.
BMC Anesthesiol. 2023 Dec 11;23(1):407. doi: 10.1186/s12871-023-02367-8.
We aimed to evaluate whether a single dose of ketamine or dexmedetomidine before induction of general anesthesia could reduce the incidence of postoperative delirium (primary outcome) or cognitive dysfunction (secondary outcome) in elderly patients undergoing emergency surgery.
This randomized, double-blinded, placebo-controlled trial included 60 elderly patients who were scheduled for emergency surgery. The patients were randomly assigned into one of three groups (n = 20): group I received 0.9% normal saline, group II received 1 µg/kg dexmedetomidine, and group III received 1 mg/kg ketamine right before anesthesia induction. Patients were observed for three days after surgery and tested for postoperative delirium and cognitive dysfunction using the delirium observation screening scale and the mini-mental state examination score, respectively.
The dexmedetomidine group had the lowest incidence of delirium (p = 0.001) and cognitive dysfunction (p = 0.006) compared to the ketamine and placebo groups. The multivariate logistic regression model revealed that dexmedetomidine reduced the incidence of postoperative delirium by 32% compared to placebo (reference) (OR = 0.684, 95% CI: 0.240-0.971, p = 0.025), whereas ketamine increased the risk by threefold (OR = 3.012, 95% CI: 1.185-9.681, p = 0.013). Furthermore, dexmedetomidine reduced the incidence of postoperative cognitive dysfunction by 62% (OR = 0.375, 95% CI: 0.091-0.543, p = 0.012), whereas ketamine increased the risk by 4.5 times (OR = 4.501, 95% CI: 1.161-8.817, p = 0.006).
A single pre-anesthetic bolus of dexmedetomidine is a practical choice for preventing postoperative delirium in elderly patients undergoing emergency surgery.
This study was approved by the Ethics Committee of Aswan University Hospital (approval number: aswu/548/7/2021; registration date: 06/07/2021) and registered on ClinicalTrials.gov (NCT05341154) (22/04/2022).
我们旨在评估全身麻醉诱导前单次给予氯胺酮或右美托咪定是否可以降低接受急诊手术的老年患者术后谵妄(主要结局)或认知功能障碍(次要结局)的发生率。
这是一项随机、双盲、安慰剂对照试验,纳入了 60 名计划接受急诊手术的老年患者。患者被随机分为三组(每组 20 人):I 组给予 0.9%生理盐水,II 组给予 1μg/kg 右美托咪定,III 组在麻醉诱导前给予 1mg/kg 氯胺酮。术后三天观察患者,分别采用谵妄观察筛选量表和简易精神状态检查评分评估术后谵妄和认知功能障碍。
与氯胺酮和安慰剂组相比,右美托咪定组谵妄(p=0.001)和认知功能障碍(p=0.006)的发生率最低。多变量逻辑回归模型显示,与安慰剂(参考)相比,右美托咪定降低了术后谵妄的发生率 32%(OR=0.684,95%CI:0.240-0.971,p=0.025),而氯胺酮则使风险增加了三倍(OR=3.012,95%CI:1.185-9.681,p=0.013)。此外,右美托咪定降低了术后认知功能障碍的发生率 62%(OR=0.375,95%CI:0.091-0.543,p=0.012),而氯胺酮则使风险增加了 4.5 倍(OR=4.501,95%CI:1.161-8.817,p=0.006)。
全身麻醉诱导前单次给予右美托咪定是预防急诊手术老年患者术后谵妄的一种实用选择。
本研究得到了阿斯旺大学医院伦理委员会的批准(批准号:aswu/548/7/2021;批准日期:06/07/2021),并在 ClinicalTrials.gov 上注册(NCT05341154)(2022 年 4 月 22 日)。